Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Tom Weijnen is active.

Publication


Featured researches published by Tom Weijnen.


Archive | 2003

Guidelines for analysing and reporting EQ-5D outcomes

Paul F. M. Krabbe; Tom Weijnen

The EQ-5D is used in different fields of research, each field with its own scientific traditions. These traditions are reflected in different methods of analysis, application, and presentation. The particular interest of a researcher may determine whether 1 or more of the 3 parts (descriptive system, VAS, index) of the EQ-5D will be applied. This chapter presents an overview of the major types of application of the EQ-5D. First, 3 fields of research are discussed, each orientated to a particular research question. Second, the 3 main types of study design are outlined. Third, guidelines for the collection of EQ-5D data are presented. Fourth, guidelines for analysing and reporting EQ-5D outcomes are presented for each of these different research strategies.


Archive | 2003

A comparison of EQ-5D time trade-off values obtained in Germany, The United Kingdom and Spain

Jan J. V. Busschbach; Tom Weijnen; Martin Nieuwenhuizen; Siem Oppe; Xavier Badia; Paul Dolan; Wolfgang Greiner; Paul Kind; Paul F. M. Krabbe; Arto Ohinmaa; Montserrat Roset; Harri Sintonen; Aki Tsuchiya; Alan Williams; John Yfantopoulos; Frank de Charro

EQ-5D has been valued using a standardised TTO by general population samples in 3 different European countries: Spain, Germany and the United Kingdom (Badia et al, 2001; Claes et al,1999; Dolan, 1997). This has created an opportunity to compare TTO values for health states between countries. These types of comparisons are rare and those submitted or publicised are bilateral (Badia et al, 2001; Claes et al, 1999). Moreover, such comparisons do not usually involve the general public (Bleichrodt & Johannesson 1997) and tend to use VAS instead of TTO. For this reason, little is known about variations in health state valuations between countries using TTO. Hence it is not known if the results of decision analyses and cost-effectiveness analyses involving utility measurement in 1 country can be generalised to other countries. It would thus be helpful if more were known about international differences in TTO values. In this chapter, we report on the mutual efforts of several research groups within the EuroQol Group to make an international comparison of TTO values. On the basis of this comparison, general guidelines are formulated for the exchangeability of TTO value sets between different countries.


Archive | 2003

Comparison of EQ-5D VAS valuations: analysis of background variables

Harri Sintonen; Tom Weijnen; Martin Nieuwenhuizen; Siem Oppe; Xavier Badia; Jan J. V. Busschbach; Wolfgang Greiner; Paul F. M. Krabbe; Arto Ohinmaa; Montserrat Roset; Frank de Charro

Preference-based instruments for measuring HRQoL of life have been developed in different countries and applied in empirical research in a much wider range of countries. A major concern in this context has been whether the valuations (values or utility weights) elicited for the instrument in 1 country are applicable in another, that is, whether the valuations in terms of the relative values/utilities of different health states are similar or not. If they are, an instrument that has been valued in country A can be applied in country B without having to carry out a very cumbersome and expensive process of eliciting the valuations in country B. However, if the valuations differ, the use of an instrument with valuations from country A in country B, for example in the evaluation of health interventions, may lead to different results and a different order of preference among the interventions from those should valuations from country B have been available.


Archive | 2003

Construction of the EQ-net VAS and TTO databases

Tom Weijnen; Martin Nieuwenhuizen; Arto Ohinmaa; Frank de Charro

One of the objectives of the EQ-net project was to create an integrated database containing valuation data gathered previously in different European countries and in different studies. This database would enable secondary cross-national and comparative data analysis to be undertaken.


Expert Review of Pharmacoeconomics & Outcomes Research | 2005

Development of a questionnaire to assess the quality of care in Dutch dialysis centers from the patient’s perspective

Mark Oppe; Tom Weijnen; Frank de Charro

This study aimed to develop and test a questionnaire in order to assess the quality of care in Dutch dialysis centers from the patient’s perspective. The questionnaire is referred to as the Quality of Care in Dialysis centers Questionnaire. Focus group sessions were organized and the results were transformed into a 68-item test version of the Quality of Care in Dialysis centers Questionnaire. Factor analyses and item reduction were performed to construct the Quality of Care in Dialysis centers Questionnaire. The questionnaire has four dimensions: doctors, nurses, other staff members and facilities; with eight descriptive items plus one item to measure satisfaction per dimension. A visual analog scale was added to determine overall satisfaction. The Quality of Care in Dialysis centers Questionnaire is used in Dutch dialysis centers. Further research should be conducted to establish preference weights per dimension on the basis of the visual analog scale scores.


Value in Health | 2001

PHP17: A EUROPEAN HEALTH STATUS INDEX BASED ON PREFERENCES OF THE GENERAL PUBLIC

F De Charro; Rosalind Rabin; Tom Weijnen

with the introduction of generic lovastatin, atorvastatin was launched and appeared to benefit from the decline in A&P of lovastatin, as did pravastatin. CONCLUSION: Evidence exists in each of the three markets reviewed to support the hypothesis for two of the three therapeutic classes investigated. There appeared to be a trend toward a significant increase in growth in competitive branded compounds in both the SSRI and statin markets following introduction of the first generic drug.


European Journal of Health Economics | 2003

A single European currency for EQ-5D health states. Results from a six-country study

Wolfgang Greiner; Tom Weijnen; Martin Nieuwenhuizen; Siem Oppe; Xavier Badia; Jan J. V. Busschbach; Martin Buxton; Paul Dolan; Paul Kind; Paul F. M. Krabbe; Arto Ohinmaa; David Parkin; Montserat Roset; Harri Sintonen; Aki Tsuchiya; Frank de Charro


Nephrology Dialysis Transplantation | 2003

Economic impact of extended time on peritoneal dialysis as a result of using polyglucose: the application of a Markov chain model to forecast changes in the development of the ESRD programme over time.

Tom Weijnen; Henk W. van Hamersvelt; Paul M. Just; Dick G. Struijk; Yuvan I. Tjandra; Piet M. ter Wee; Frank de Charro


Value in Health | 2003

PRK13: DEVELOPMENT OF A QUESTIONNAIRE TO ASSESS QUALITY OF CARE IN DUTCH DIALYSIS CENTERS

Mark Oppe; Tom Weijnen; F De Charro


Value in Health | 2002

PUK1 A COMPARISON OF PD AND HD PATIENT SURVIVAL ALLOWING FOR SWITCHES FROM PD TO HD

Tom Weijnen; F De Charro

Collaboration


Dive into the Tom Weijnen's collaboration.

Top Co-Authors

Avatar

Frank de Charro

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Martin Nieuwenhuizen

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Paul F. M. Krabbe

Radboud University Nijmegen Medical Centre

View shared research outputs
Top Co-Authors

Avatar

Jan J. V. Busschbach

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Siem Oppe

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mark Oppe

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Paul Dolan

London School of Economics and Political Science

View shared research outputs
Researchain Logo
Decentralizing Knowledge